A PHASE II DOUBLE-BLINDED PLACEBO-CONTROLLED RANDOMIZED TRIAL OF SALVAGE RADIOTHERAPY WITH OR WITHOUT ENHANCED ANTI-ANDROGEN THERAPY WITH APALUTAMIDE IN RECURRENT PROSTATE CANCER

Brief description of study

The purpose of this study is to compare any good and bad effects of using the drug apalutamide (study drug) along with usual radiation therapy to using usual radiation therapy alone. The study drug is a hormone suppression drug. The study drug is FDA approved for the treatment of non-metastatic castration resistant prostate cancer, however the study drug is still considered investigational in this trial setting. The addition of the study drug to usual radiation could shrink your cancer/prevent it from returning, but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the study drug should reduce the chance of your cancer growing back compared to the usual approach.


Clinical Study Identifier: s18-00819
ClinicalTrials.gov Identifier: NCT03371719
Principal Investigator: Peter B. Schiff
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.